| Value | ₹29.00 Cr |
|---|---|
| Execution period | 60-90 days |
NSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,705.00
- Market cap
- ₹99,027 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.1×Sector 37.9×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Aurobindo Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.
Aurobindo Pharma Results Update
Aurobindo Pharma reported Q2 FY27 revenue of Rs.10,263 Crore, up 23.9% YoY, and net profit of Rs.1,124 Crore. An interim dividend of Rs.7 per share was declared.
Aurobindo Pharma Q2 FY27 Results: Net Profit ₹1,124 Cr, Up 32.5% YoY
Aurobindo Pharma Ltd reported revenue from operations of ₹10,263 Cr (+23.9% YoY) and net profit of ₹1,124 Cr (+32.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,124 Cr · +32.5% YoY
Other merger & restructuring announcements
All →Max Estates Merger & Restructuring Worth ₹0.01 Cr
Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.
- Value
- ₹0.01 Cr
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr
HEG Advanced Materials Merger & Restructuring Worth ₹10.12 Cr
HEG Advanced Materials closed LNJ Trading FZCO, its Dubai-based wholly owned subsidiary, as part of overseas structure rationalisation. The filing quantifies the effect at AED 4,048,000.
- Value
- ₹10.12 Cr
Saregama India Merger & Restructuring
Saregama India's board approved closing its wholly owned Dubai subsidiary, Saregama FZE, which has no ongoing operations. The closure is not expected to materially affect business operations.
Jindal Poly Films Merger & Restructuring
Jindal Poly Films' step-down subsidiary, JPF API Laminates UK Limited, was dissolved effective November 3, 2026. It has ceased to be a subsidiary of the company.